Current Rheumatology Reports

, 16:405

Management of Recurrent Thrombosis in Antiphospholipid Syndrome

Authors

  • Cecilia Nalli
    • Rheumatology and Clinical Immunology, Department of Clinical and Experimental SciencesSpedali Civili and University of Brescia
    • Rheumatology ChairUniversity of Pavia
  • Laura Andreoli
    • Rheumatology and Clinical Immunology, Department of Clinical and Experimental SciencesSpedali Civili and University of Brescia
  • Cinzia Casu
    • Rheumatology UnitNiguarda “Ca’ Granda” Hospital
    • Rheumatology and Clinical Immunology, Department of Clinical and Experimental SciencesSpedali Civili and University of Brescia
ANTIPHOSPHOLIPID SYNDROME (D ERKAN, SECTION EDITOR)

DOI: 10.1007/s11926-013-0405-4

Cite this article as:
Nalli, C., Andreoli, L., Casu, C. et al. Curr Rheumatol Rep (2014) 16: 405. doi:10.1007/s11926-013-0405-4
Part of the following topical collections:
  1. Topical Collection on Antiphospholipid Syndrome

Abstract

One of the challenges of managing patients with antiphospholipid syndrome is the prevention of rethrombosis (secondary prophylaxis). Risk stratification, i.e. traditional cardiovascular and thrombosis risk factors, systemic autoimmune diseases, antiphospholipid antibody profile, and the intensity of anticoagulation are all relevant to the management of APS patients with recurrent thrombosis. The paper will review “state of the art” strategies for optimizing therapy for APS patients with recurrent thrombosis.

Keywords

Antiphospholipid antibodies Anticardiolipin antibodies Anti-β2glycoprotein I antibodies Lupus anticoagulant Thrombosis Recurrent thrombosis Stroke Primary antiphospholipid syndrome Cardiovascular risk factors Warfarin Low-dose aspirin Hydroxychloroquine Statins Heparin Rituximab Management

Copyright information

© Springer Science+Business Media New York 2013